key: cord-0684470-jln4wk3n
authors: Wan, Hongbin; Aravamuthan, Vibhas; Pearlstein, Robert A.
title: Probing the dynamic structure-function and structure-free energy relationships of the corona virus main protease with Biodynamics theory
date: 2020-07-20
journal: bioRxiv
DOI: 10.1101/2020.07.19.211185
sha: 0903163c8449a04fe4df0f9aa8dac6b58a29866d
doc_id: 684470
cord_uid: jln4wk3n

The SARS-CoV-2 Main protease (Mpro) is of major interest as an anti-viral drug target. Structure-based virtual screening efforts, fueled by a growing list of apo and inhibitor-bound SARS-CoV/CoV-2 Mpro crystal structures, are underway in many labs. However, little is known about the dynamic enzyme mechanism, which is needed to inform both structure-based design and assay development. Here, we apply Biodynamics theory to characterize the structural dynamics of substrate-induced Mpro activation, and explore the implications thereof for efficacious inhibition under non-equilibrium conditions. The catalytic cycle (including tetrahedral intermediate formation and hydrolysis) is governed by concerted dynamic structural rearrangements of domain 3 and the m-shaped loop (residues 132-147) on which Cys145 (comprising the thiolate nucleophile and one-half of the oxyanion hole) and Gly143 reside (comprising the other half of the oxyanion hole). In particular: Domain 3 undergoes dynamic rigid-body rotations about the domain 2-3 linker, alternately visiting two conformational states (denoted as ). The Gly143-containing crest of the m-shaped loop (denoted as crest B) undergoes up and down translations in concert with the domain 3 rotations (denoted as , whereas the Cys145-containing crest (denoted as crest A) remains statically in the up position. The crest B translations are driven by conformational transitions within the rising leg of the loop (Lys137-Asn142). We propose that substrates associate to the state, which promotes the state, dimerization (denoted as -substrate), and catalysis. The structure resets to the dynamic monomeric form upon dissociation of the N-terminal product. We describe the energetics of the aforementioned state transitions, and address the implications of our proposed mechanism for efficacious Mpro inhibition under native-like conditions.

. Hypothetical examples of post-cleaved M pro buildup and decay and downstream cleavage products (reflecting substrate association, dissociation, and turnover in aggregate) under the two general scenarios described in the text (the mathematical basis of these plots is explained in [1] ).

(A) The worst case scenario, in which the rate of product buildup is comparable to ki. The plot includes the following quantities: auto-cleaved M pro buildup (green tracing) (noting that M pro decay depends on the existence of a degradation pathway), collective product buildup (purple tracing), and buildup and decay of inhibitor-bound M pro under conditions in which the inhibitor kon  ki (blue tracing), and inhibitor kon < ki (red tracing). (B) Same as A, except for the best case scenario, in which the rate of product buildup < ki.

We collected, classified, and overlaid representative dimeric and monomeric ligand-bound and apo SARS-CoV and CoV-2 M pro crystal structures (see Materials and methods). We then explored and compared the structures using an integrated approach, consisting of 3D visualization and molecular dynamics (MD)-based solvation analysis (WATMD [2, 15] ) to qualitatively assess the free energy barriers governing the intra-molecular states of M pro (denoted as monomeric 1 and 2 , and dimeric 2 • 2 ), as well as the association and dissociation barriers governing substrate and inhibitor occupancy. We then investigated the structure and function of M pro , focusing on the interrelationship between the catalytic and substrate/inhibitor-binding mechanisms. Questions of interest include:

1) The basis of substrate-and dimer-induced activation and specificity of the catalytic site.

2) The interplay between covalent/mechanism-based inhibitor binding kinetics and the structural dynamics of the protein.

3) The interplay between catalytic turnover and viral dynamics governing the buildup of postcleaved M pro and its substrates.

Monomeric M pro consists of three domains, including domain 3 and domains 1 and 2 that together subserve the protease function ( Figure 2A ) [16] . Domains 1, 2, and 3 respectively comprise the "ceiling", "floor", and "basement" of the active site (AS), and are organized in a loosely packed arrangement that promotes high sensitivity of protein structure-function to the monomeric versus dimeric forms, the pre-versus post-cleaved species, and the unbound versus substrate-bound states. Domains 1 and 2 versus domains 2 and 3 are connected by short and long flexible linkers, respectively, resulting in a tighter 1-2 inter-domain relationship compared with the looser, more dynamic relationship among domains 2 and 3. We denote this hierarchical inter-domain relationship as {1-2}-3, consistent with the crystallographically observed conformations in the monomeric 1 and 2 states (PDB code = 2QCY) and the dimeric 2 • 2 form (PDB code = 6M03, 2Q6G, and many others) (noting that monomeric 2 is unobserved experimentally).

The backbone NH groups comprising the oxyanion hole (contributed by Cys145 and Gly 143) reside on a three-dimensional double-crested m-shaped loop, hereinafter denoted as the "m-shaped loop" (Figure 2B ). The N-terminal leader sequence (denoted as NTL) and C-terminal tail sequence (denoted as CTT), the latter of which includes a small C-terminal helix, play key roles in organizing the AS, m-shaped loop, and dimer interface. We assume in this work that the substrate binding and catalytic machineries are well-conserved in CoV and CoV-2, which differ by 12 residues, half of which are located in domain 1 (including one located at the upper boundary of the AS), two in domain 2, and four in domain 3 [17] ). As such, CoV and CoV-2 structures were used interchangeably in our analysis. Serine proteases function via a common catalytic mechanism conveyed by an Asp-His-Ser triad.

However, a His-Cys dyad appears sufficient for proton abstraction from the more acidic Cys (relative to Ser) of cysteine proteases, leading to an activated thiolate-His ion pair [19] [20] [21] . The M pro catalytic mechanism may be summarized as follows (the residue numbering throughout this work refers to the SARS-CoV-2 variant):

1) Abstraction of the Cys145 proton by His41, resulting in a nucleophilic thiolate moiety (stage 1 proton transfer).

2) Substrate binding, followed by nucleophilic attack on the scissile bond, resulting in a transient tetrahedral intermediate (TI) which is stabilized by the backbone NH dyad comprised of Gly143 and Cys145 (referred to as the "oxyanion hole"). This step is claimed to be extremely fast in other cysteine proteases (requiring stopped flow measurement) [20] .

3) Spontaneous TI decay to the N-terminal leaving group (product 1) and thioester adduct. 4 ) Hydrolysis of the thioester adduct (stage 2 proton transfer), resulting in the C-terminal leaving group (product 2). This step is claimed to be rate-determining in other cysteine proteases [22] .

However, alternate catalytic triad-based mechanisms have been proposed M pro , including: 1) Substitution of the canonical Asp of the catalytic triad by a high occupancy water molecule observed near His41 in many M pro crystal structures and our WATMD calculations (possibly a weaker surrogate for Asp) [21, 23] , noting the absence of this water in subunit B of 2Q6G due to repositioning of Asp187 (which if catalytically essential, would result in enzyme inactivation).

2) Rearrangement of Asp187 from its observed pairing with Arg40 to His41 [13] . Given the strategic location of the Arg40-Asp187 ion pair opposite to the domain 1-2 linker in all of the structures that we examined (exhibiting a latch-like appearance), stabilization of the domain 1-2 interface by this shielded ion pair is the more likely scenario (Figure 3 ). 

All M pro structures used in our study were obtained from the RCSB databank [24] , and grouped according to species, site-directed mutants, ligand/substrate-bound forms, and dimeric and mutant monomeric forms (Table 1) . 

Whereas drug-target binding and efficacy are considered in terms of equilibrium free energy models throughout mainstream cell biology and pharmacology, it is apparent that living systems (including virally infected cells) depend to a very large degree on non-equilibrium operation. We previously reported a first principles theoretical treatment of non-equilibrium structure-functionfree energy relationships referred to as Biodynamics [1, 2] . Spontaneous non-covalent intra-and inter-molecular interactions, by definition, lower the total system free energy (i.e. G = Gnoninteracting -Ginteracting < 0). However, G is a non-sequitur under conditions in which the concentrations of the participating species are changing over time (non-equilibrium conditions, by definition), in which case binding free energy is partitioned into distinct barriers governing the rates of entry and exit to/from each available structural state (denoted as Δ ‡ , Δ ‡ ). Fractional occupancy of a given state is proportional to the relative rates of entry and exit to/from that state (versus G = RT • ln(Kd)), wherein the entry-exit process can cycle throughout the lifetimes of the participating species (see below). We proposed previously that, under aqueous conditions, Δ ‡ and Δ ‡ respectively equate to the de-solvation and re-solvation costs of entering and exiting non-covalent states [2] . The de-solvation cost equates to the total loss of hydrogen bond (H-bond) free energy from the expulsion of H-bond enriched solvation from the intra-or inter-molecular interface to bulk solvent, whereas the re-solvation cost equates to the total loss of H-bond free energy of water returning from bulk solvent to H-bond depleted positions of the interface.

Polar/charged solute surfaces promote H-bond enriched solvation relative to bulk solvent, resulting in free energy gains. The de-solvation cost of such water during intra-or inter-molecular rearrangements depends on the extent to which the disrupted H-bonds are replaced by intra-or inter-molecular counterparts (typically, a zero sum game at best). The rate of entry to a given state is proportional to the de-solvation cost of that state, and occupancy increases with increasing rate of entry at a constant rate of exit. The rate of exit from a given state is proportional to the resolvation cost of that state, and occupancy increases with decreasing rate of exit at a constant rate of entry. As such, the occupancy of a given state may accumulate via fast entry, slow exit, or both (to the limit of the total Δ ‡ and Δ ‡ ). Energetically favorable charged/polar interactions, including charge-charge, charge-neutral, and neutral-neutral, drive protein folding and rearrangements of folded macromolecules under aqueous conditions by:

1) Lowering the total de-solvation cost via optimal mutual water H-bond replacements (thereby speeding the rate of entry).

2) Electrostatic free energy gains in shielded charge-charge scenarios (thereby slowing the rate of exit).

The energetic driving force of all non-covalent rearrangements (including protein folding) consists principally of the expulsion of H-bond depleted solvation. The persistence of a given state depends on the total free energy of the expelled solvation (amounting to the re-solvation cost incurred upon exiting). Persistent states result from complete expulsion of H-bond depleted solvation, whereas cyclic rearrangeability depends on a "whack-a-mole-like" scenario, in which expulsion of H-bond depleted solvation from one region is accompanied by the generation of an equivalent amount at another (resulting in an oscillation between the contributing states-a kind of molecular "motor").

Solvation calculations were performed using our in-house WATMD software, as described previously [2] . Briefly, the prepared protein structures (corrected for proton states, Asn/Gln and His flips, missing atoms, and net charge) were simulated in AMBER 16 with ff14SB force-field [30] at 300 o K without restraints using periodic boundary conditions in a TIP3 water box of 8 Å between any protein atom and the edge of the box. The simulations consisted of a 0.5 ns equilibration phase, followed by a 10 ns production phase sufficient to achieve convergence of the solvating water, resulting in 40,000 frames per trajectory. pH-dependent M pro structure and substrate recognition, and the possibility of pH-driven structure switching has been suggested by other workers on the basis of the observed pH dependence of M pro structure [16, 31] . However, M pro appears to operate exclusively within the cytoplasmic double membrane vesicle environment, the pH of which is likely ~7.0-7.4 in the absence of proton pumps. As such, M pro simulations at pH 7.0 seem justified.

The 40,000 frame AMBER trajectories were first aligned to a common reference frame about a specified set of template residues, and analyzed in terms of time-dependent water occupancy (i.e.

the frequency of water visits) within each 1 Å voxel of a three-dimensional lattice containing the time-averaged protein structure. H-bond enriched and depleted solvation regions were assigned on the basis of high (un-trapped or trapped) and low occupancy voxels relative to bulk solvent, respectively. The resulting water occupancies >> bulk and << bulk (denoted as hotspots) are represented by color-coded spheres, the radii of which are proportional to the occupancy level.

The color-coding is based on a gradient representing the strength and type of the protein H-bond partner(s): strong donor (bright red)  weak/deficient partner (light pink/light blue/white)  strong acceptor (bright blue). Solvating water was assumed to be stationary relative to flexible protein substructures (analogous to a boundary layer effect), necessitating separate substructurespecific water occupancy analyses (specified by substructure-specific alignment templates). For example, the Met164-Glu166 -strand in domain 2, a key AS element that undergoes significant motion during the simulations (shown in yellow in Figure 2 ), was used as the template for generating the solvation structure within and around the binding pocket (noting however that bound ligands in all crystal structures are agnostic to this motion). We calculated the solvation structures of the following M pro states, from which we inferred the solvation free energy barriers governing the 1/  2/ and 2 • 2/ state transitions, together with substrate and inhibitor association and dissociation barriers:

1) The apo form of monomeric 1/ (2QCY) and putative substrate-bound form of monomeric 2/ (PDB code = 2Q6G with one chain removed), focusing on:

a) The AS solvation structure in 2QCY, which informs about substrate k1, k-1 and inhibitor kon, koff. We examined the correspondences between the solvation hotspots and a set of representative inhibitors ( Table 2 ) extracted from additional CoV and CoV-2 M pro structures, which we overlaid on the 2QCY time-averaged protein structure.

b) The domain 2-3 interface in 2QCY and 2Q6G, which informs about the 1/  2/ transition barrier.

c) The pre-dimer interface in a single subunit of 2Q6G, which informs about the monomer  dimer transition barrier.

2) The apo form of dimeric 2 • 2/ in 6M03, focusing on the AS solvation structure (hypothetical).

3) The boceprevir-bound form of dimeric 2 • 2/ (PDB code = 6WNP), focusing on the occupied AS solvation structure, which informs about the residual solvation of the bound state (H-bond enriched slows substrate k-1; inhibitor koff). 

Analysis of the M pro crystal structures in our study suggests the existence of a complex substratebinding mechanism in both CoV and CoV-2 variants. This mechanism can be dissected into four 2) Cooperative state transitions between domain 3 and the rising leg of the m-shaped loop, in which the lower energy 310 helix melts into the higher energy extended chain (denoted together as 1/  2/ ). The free energy difference between these states is attributable to solvation-mediated rearrangements (see below). Monomeric 1/ is ruled out by our mechanism, and monomeric 2 is highly transient (noting that neither of these states is observed experimentally).

3) Cognate substrate and inhibitor binding to 1 , which transiently stabilizes both the dimerization-competent monomeric 2/ state and the dimeric 2 • 2/ state.

We postulate that dimerization occurs more slowly in the unbound 2 state, which is consistent with the higher observed substrate-independent Kd [32] (see below). The C-terminal helix and NTL in 1/ (yellow) and 2/ (red). This helix, which is rotated toward the left in 1/ overlaps with the NTL in 2/ (circled in red), and as such, is pushed away in the 1/ state (blue arrow pointing toward the southwest). The Lys5-Gln127 H-bond is disrupted in this altered NTL trajectory, which signals into Tyr118 and Tyr126 via the -hairpin.

Next, we examined the B-factors in the monomeric ( 1/ ) and several dimeric (2 • 2/ ) crystal structures as a qualitative metric of the energetic stability of the H-bond network ( Figure   10 ). The data suggests that the H-bond network in the 1/ state is stable (B-factors ranging largely between white/light blue/dark blue) ( Figure 10A ), compared with the significantly less stable network in the dimeric apo 2 • 2/ state (B-factors ranging between white/pink/bright red) ( Figure 10B ). The B-factors of the cognate substrate-bound structure ( Figure 10C ) are only slightly warmer than those of 1/ , consistent with substrate-mediated stabilization of the 2 • 2/ form. The boceprevir-bound 2 • 2/ B-factors are comparable to those of the substrate-bound structure ( Figure 10D ), whereas those of the N3 bound structure are far warmer (nearly comparable to the apo structure) ( Figure 10E ). The non-native 2 • 2/ state (PDB code = 2BX3), in which the extended m-shaped loop conformation ordinarily found in this state has been short-circuited, is consistent with the warm B-factors in the rising leg of the loop ( Figure   10F ). We propose that the rigid-body rotation of domain 3 between the 1/ and 2/ states is subserved by alternating de-solvation and re-solvation of polar and charged side chains and backbone groups (which, according to our WATMD results, are solvated by H-bond depleted water) positioned within the domain 2-3 interface ( Figure 11 ). New H-bond depleted solvation appears in the wake of domain 3 rearrangements, such that the net reduction of unfavorable solvation free energy is never achieved in either configuration (see below). 

The m-shaped loop, which contains the catalytic Cys (resident on crest A) and oxyanion hole (resident on crests A and B), is common to all members of the chymotrypsin family, although the structural properties of these enzymes vary. Crest B of M pro switches between the down (S1 pocketaccessible) ( Figure 12A ) and up (S1 pocket-inaccessible) positions ( Figure 12B ), corresponding to the 1/ and 2/ states of the enzyme, respectively. The S1 pocket switches between the open/oxyanion hole misaligned and closed/oxyanion hole aligned states in 1/ and in 2/ , respectively. Although access to the S1 pocket is sterically blocked by Asn142 in the crest B up position, the cavity itself remains intact and occupiable (as such, Asn142 acts as a gatekeeper rather than a plug) ( Figure 12C ). We postulate that the complex m-shaped loop mechanism of M pro is tailored for lowering the high de-solvation cost of the polar P1 Gln side chain during substrate association to the S1 pocket. The need for this mechanism is obviated in hepatitis C NS3 protease and chymotrypsin due to their preference for Cys/Thr and aromatic P1 side chains, respectively.

As such, the m-shaped loops of these proteins are instead rigidified via an extra crest in NS3 (Figures 13A) and a disulfide bond to an adjacent chain in chymotrypsin ( Figure 13B ), resulting in permanent S1 pocket accessibility ( Figures 13C-D) .

We explored the 1/  2/ transition mechanism in M pro by comparison of the monomeric and representative dimeric CoV and CoV-2 structures to better understand the functional purpose and detailed structural and energetic basis of the up/down bidirectional state transition of crest B.

We now turn to:

1) The conformational properties of the m-shaped loop in the 1/ and 2/ states.

2) The means by which m-shaped loop and domain 3 conformational dynamics are coupled.

3) The role of m-shaped loop conformational dynamics in governing the S1 pocket properties and P1 Gln de-solvation mechanism. 2) The rising leg of the m-shaped loop contributes to the lining of the S1 pocket (addressed in the following section). 

Dimer-independent catalytic activity of pre-cleaved M pro was observed by Chen et al., who nevertheless proposed the existence of an "intermediate" dimeric form of the enzyme [33] . A more plausible explanation is that pre-cleaved M pro exists exclusively as monomers embedded within the polyprotein, whereas the post-cleaved species necessarily exists as a mixture of monomers and dimers, in which the monomeric form binds substrates that are cleaved by the dimeric form (such that << ). The pre-cleaved monomeric form of M pro cannot be fully represented in 2QCY because the C-terminal peptide is spatially far from the AS (noting that the Gln306 C-terminus serves as the P1 residue of the pre-cleaved protein). We propose the existence of two distinct forms of monomeric M pro , consisting of:

1) The post-cleaved species captured in 2QCY.

2) An alternate pre-cleaved polyprotein-embedded form, in which the C-terminal peptide b) The remainder of the polyprotein exiting from the prime side of the pocket (noting that M pro folding likely occurs after nsp4 cleavage).

We postulate that cis cleavage is facilitated in the 1/ state, in which domain 3 is rotated toward the AS, and the C-terminal region of this domain (including the CTT helix) is partially unfolded (Figure 16 ). In the absence of this helix, the NTL is free to adopt the active Lys5-Gln127

H-bond-disrupted state that exists in all 2/ structures (i.e. a hybrid 1/ state). 

The M pro catalytic cycle depends integrally on the dynamic intra-molecular rearrangements and 2/ is shown in Figure 17B and 17C, respectively), noting that the chain inserts into the AS in the N-to C-terminal direction. Dissociation of the C-terminal leaving group has no impact on the intra-molecular/dimeric state of M pro ( Figure 17D ), whereas that of the N-terminal leaving group resets the enzyme to the monomeric 1/ state ( Figure 17E) . 2) Closing the S1 pocket via the crest B down  crest B up transition, which repositions the Asn142 gatekeeper over the pocket. We postulate that the cost of de-solvating the polar amide group of the P1 Gln side chain is reduced via this mechanism, such that the side chain binds with its solvation partially intact (noting that the S1 pocket is fully open in the Access to the S1 pocket is blocked by Asn142 in the extended 2/ state ( Figure 19A ), which is pointed away in the 310 helical 1/ state ( Figure 18A ). As such, we postulate that substrates bind to the 1/ state, which then rotates about the domain 2-3 linker into the substratestabilized 2/ state, followed by dimerization.

Dimerization is widely assumed to govern both the activation and substrate complementarity of M pro [34] . 

Enzyme kinetics are typically measured and analyzed under the assumption that the rate of enzyme-substrate complex formation and turnover are equivalent (the steady state assumption).

However, this assumption need not apply under native cellular conditions, in which the enzyme and substrate concentrations vary over time, and the rate of enzyme-substrate complex formation is necessarily described using ordinary differential equations (ODEs) of the form:

where ES denotes the enzyme-substrate complex, and k1, k-1, and kcat denote the association, dissociation, and turnover rates, respectively. At constant free enzyme and substrate transitioning, substrate binding, and dimerization), which is described by the following set of coupled ODEs corresponding to the reaction scheme summarized in Figure 26 :

where kexp and kdeg are the rates of monomer synthesis and monomer degradation, respectively (assuming the possible existence of one or more protein degradation pathways). 

where k1(1) and k-1(1) are the rates of M pro -substrate association and dissociation, respectively, and kb(2) and kb(-2) are the rocking rates between the two domain 3 positions in the substrate-bound M pro monomer. where product 1 is the hydrolyzed C-terminal product, kon(1), koff(1), and kcat(1) are the rates of dimerization, dimer-substrate dissociation, and turnover, respectively

where 2 • ( 2/~ℎ ) is the thioester adduct, which is equal to the rate of product 1 generation.

where product 2 is the hydrolyzed C-terminal product, and kcat (2) is the turnover rate constant for thioester adduct decay (where the functional unit is dimeric).

Under non-equilibrium conditions, the catalytic efficiency of M pro depends on synchronous dimerization, substrate binding, and turnover, equating to:

1) A substrate-2/ association rate approaching the turnover rate (k1(1) ≳ kcat). The slowest binding step is otherwise rate-determining.

2) A dimer (2 • ( 2/~) ) lifetime on the order of the reaction time constant

(1/koff(1) < 1/kcat). Turnover is disrupted when the dimer and/or bound substrate dissociate prior to product formation (noting that Kd is agnostic to binding partner exchanges, whereas enzyme-mediated turnover is not [5] ). For non-covalent inhibitors:

[~ℎ

where kon(2) and koff(2) are the inhibitor association and dissociation constants, respectively.

We assume that inhibitors bind to the 310 helical state of the m-shaped loop.

For reversible covalent thioester inhibitors: 2) kcat ranging between 0.05 and 0.178 s -1 , compared with the median kcat of 13.7 s -1 reported for 1,942 enzymes. Slow turnover by CoV 3CL pro has been attributed to slow hydrolysis of the acyl adduct (reaction step 2), rather than slow proton abstraction or TI formation (reaction step 1) [20] .

3) kcat/KM ranging between 219 and 859 M -1 s -1 , compared with the median kcat/KM of 125E3

reported for 1882 enzymes. The kcat/KM equates to unrealistically slow processing throughput (e.g. ~1 mM of substrate is needed to achieve an overall processing rate of 1 s -1 , compared with 8 M at the median kcat/KM). [35] . In practice, dimer buildup is a nonequilibrium process due to the time-dependence of the total M pro and polyprotein concentrations resulting from first order auto-cleavage, and furthermore, the monomer-dimer-substrate distribution is highly non-linear due to the 3-way relationship among the species. We calculated the equilibrium dimer concentration as a function of substrate-independent free monomer concentration in multiples of Kd = 5 and 0.8 M (Table 3) . It is apparent from the table that the fractional dimer concentration increases slowly as a function of total M pro concentration (i.e. dimer + monomer). A significant fraction of monomer is present at the optimal total M pro concentration, which is tipped toward the dimer in the presence of substrates. suggests that a similar protocol may be necessary for the correct measurement of M pro enzyme kinetics, which may explain the unrealistic M pro kcat/KM determined from the conventional Michaelis-Menten enzyme kinetics model.

The 2) Inhibition of M pro -mediated polyprotein cleavage in trans. We assume that most covalent inhibitors containing substrate-like P1 groups bind to the monomeric 1/ (S1 pocketaccessible) form of post-cleaved M pro .

It is reasonable to assume that efficacious inhibition at the lowest possible concentration depends on high occupancy of the AS over time (especially in the absence of M pro degradation or downregulation), which in turn, depends on kinetically tuned inhibitor binding (such that kon  ki and koff approaches the protein lifetime), as follows:

1) High complementarity between the inhibitor solvation structure and that of the monomeric M pro AS (including the Glu166 backbone -hairpin positions and S1 pocket), resulting in maximal expulsion/re-solvation cost of H-bond depleted solvation (noting that tolerance for H-bond enriched inhibitor solvation may be limited largely to the P1 position).

2) Reversible covalent reactivity needed to further slow koff beyond the re-solvation free energy contribution, the latter of which may result in an inadequate t1/2 of the bound state relative to the pharmacokinetic timescale (given the possibility that the M pro concentration does not decay over time in the absence of a degradation pathway). Rapid adduct formation is conceivable based on the general cysteine protease mechanism reported by other workers, where the rate-determining step consists of hydrolysis (step 2) rather than thioester formation (step 1) [22] .

3) Irreversible covalent inhibition is driven largely by covalent adduct accumulation, although efficacy may nevertheless depend on the accumulation rate (noting that leakage of M pro and its downstream products may result from slow accumulation due to slow kon and/or kcat Remarkable complementarity between inhibitor and substrate H-bond groups is apparent from overlays of bound M pro crystal structures on our predicted solvation structures (Figures 24 and 26) , consistent with the key de-solvation contribution to the binding free energy. Mutual mismatches between the bound inhibitors and solvation structures, together with intra-ligand de-solvation costs and entropic losses, may be reflected qualitatively in higher B-factors ( Figure 25A ). Occupancy detractors include:

1) The high entropic cost of binding flexible peptide-like substrates (reflecting the cost of ordering) also factor into the association free energy barrier.

2) The lack of an optimal P1 group, which is expected to slow kon (and possibly kcat) and speed koff due to higher inhibitor desolvation cost and indirect loss of substrate-induced enzyme activation (corresponding to the lack of alignment of the oxyanion hole in the 1/ state). Furthermore, the lack of ligand-protein solvation complementarity in the S2, S3, and S4 pockets can result in independent binding/re-binding behavior ("wagging") of the occupying P2, P3, and P4 groups (reflected in the high B-factors in 6LU7) due to local solvation free energy losses in each pocket. Such losses can result in low fractional occupancy of the closed P1 pocket across the M pro population.

From a systems perspective, efficacious inhibition/occupancy depends on reducing the active M pro population below a critical threshold (noting that all uninhibited copies can drive the downstream processes), and maintaining this inhibition level over time (keeping in mind that M pro inhibition during the virion production phase may have little impact on the disease outcome given that the ship has already sailed by then).

The primary objective of preclinical drug discovery consists of predicting chemical entities that can cure or alleviate human disease via a combination of experimental and in silico approaches. In the absence of a theoretical foundation to formulate such predictions, drug discovery is relegated to a step-wise trial-and-error process centered on empirical approaches and data fitting techniques (i.e. inductive reasoning-based). Whereas drug discovery is predicated on equilibrium drugtarget/off-target structure-free energy relationships (expressed as n • Kd or n • IC50, where n is a scaling factor between the drug concentration at 50% occupancy versus that at the efficacious occupancy), cellular function and pharmacodynamics are predicated on non-linear dynamic structure-kinetics relationships, in which targets/off-targets, their endogenous cognate partner(s) and drug concentrations vary over time. The equilibrium and non-equilibrium worlds rarely converge due in no small measure to the fact that free energy, occupancy, and concentration/exposure under in vivo conditions are not related by empirical principles (e.g. G = RT • ln(Kd), Hill equation, Michaelis-Menten equation), but instead by coupled time-dependent systemic relationships, such as those outlined for M pro in the previous section. Recognizing that cellular function/dysfunction is generated from coupled sets of dynamic solvation free energypowered molecular rearrangements (that we refer to as "physical math") is the first step toward transforming drug discovery (i.e. a predominantly data modeling-based undertaking) into drug design (a first principles theory-based undertaking). The first step is to improve the predictiveness of in vitro data via in vivo-relevant non-equilibrium dynamic measurements and models of drugtarget/off-target binding. Cellular function is inextricably linked to dynamic biomolecular concentrations and dynamic state occupancy, which are the primary currency by which information is conveyed and processed. It is evident that each molecular state is optimized by nature according to the following criteria:

1) The timescale of the processes in which the species participate (e.g. 1/kcat), such that no entry or exit step to/from a given state becomes excessively rate-determining. As such, Hbond depleted solvation is expected to be sparingly present in native binding sites (although H-bond depleted solvation plays a key role in both inter-and intra-molecular rearrangements, as well as protein folding).

2) Tuning between the transition rate to/from each molecular state and the rates of buildup and decay of the molecular species or binding site (if the train is missed, it matters not how long the trip). We showed in our previous work that optimal dynamic drug-target occupancy depends first and foremost on the drug-target association rate constant (kon, k1), and that the kon of many marketed drugs is fast, even when the koff is slow [1] .

In this work, we have attempted to identify and characterize the dynamic states of M pro , and relate the rates of buildup and decay of those states to structure-solvation free energy relationships (i.e.

de-solvation and re-solvation costs/barriers) needed to inform drug design. The general idea is to reverse-engineer sets of high potential energy solvation (relative to bulk solvent) into complementary ligand solvation structures capable of achieving efficacious non-equilibrium occupancy at their intended targets via:

1) Expulsion of H-bond depleted solvation from the binding interface.

2) Mutual H-bond replacement of H-bond enriched "gatekeeper" solvation (which is absent in the AS of M pro ) that is necessary for access to H-bond depleted solvation.

The critical question for M pro -based anti-viral therapies concerns the time-dependent uninhibited fraction of the enzyme that is incapable of sustaining viral replication, which constitutes the minimum dynamic occupancy level that efficacious inhibitors must achieve and maintain. As for cognate substrates, covalent inhibitors must associate to, and stabilize the active dimeric form of the enzyme (noting that occupancy by irreversible covalent inhibitors accumulates over time).

Accurate qualitative determination of M pro enzyme kinetics and time-dependent concentration buildup/decay of the monomeric and dimeric species (e.g. possibly measureable via replicon assays) in the context of the true substrate binding/catalytic mechanism is essential for successful drug design targeting kon, koff, and pharmacokinetic exposure. Furthermore, enzyme kinetics models must account for the dependencies between product generation and dynamic substrate, monomer, and dimer concentrations, and substrate-induced dimerization (possibly adapted from the putatively analogous caspase-1 mechanism [42] ). Furthermore, inhibitor binding dependencies that are insensitive to resistance mutations are essential. We have offered a starting point for the development of such models, stopping short of the actual design of M pro inhibitors, which is beyond the scope of this work.

We showed that the dynamic non-covalent intra-and inter-molecular rearrangements underlying M pro structure-function, consisting of intra-molecular 1/ We further showed that solvation free energy is ideally suited for powering the aforementioned rearrangements via counter-balanced, location-/state-specific H-bond enriched and depleted solvation, the de-solvation and re-solvation of which govern the rates of entry and exit of molecular populations to/from the available enzyme states (including substrate and inhibitor-bound states).

Lastly, we challenged the reported enzyme kinetics data for M pro , in which the enzyme efficiency and inhibitory requirements may be grossly underestimated by the classical Michaelis-Menten approach used in those studies.

Biodynamics: A novel quasi-first principles theory on the fundamental mechanisms of cellular function/dysfunction and the pharmacological modulation thereof

Building New Bridges between In Vitro and In Vivo in Early Drug Discovery: Where Molecular Modeling Meets Systems Biology

Toward in vivo-relevant hERG safety assessment and mitigation strategies based on relationships between non-equilibrium blocker binding, three-dimensional channel-blocker interactions, dynamic occupancy, dynamic exposure, and cellular arrhythmia. bioRxiv. Cold Spring Harbor Laboratory

Application of the Van Slyke-Cullen irreversible mechanism in the analysis of enzymatic progress cu

Processing of the SARS-CoV pp1a/ab nsp7-10 region

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response

SARS-Coronavirus Replication Is Supported by a Reticulovesicular Network of Modified Endoplasmic Reticulum

Ultrastructure of the replication sites of positive-strand RNA viruses

Dynamics of Coronavirus Replication-Transcription Complexes †

Expression and Cleavage of Middle East Respiratory Syndrome Coronavirus nsp3-4 Polyprotein Induce the Formation of Double-Membrane Vesicles That Mimic Those Associated with Coronaviral RNA Replication Downloaded from

Topographic changes in SARS coronavirus-infected cells during late stages of infection

Three-Dimensional Model of a Substrate-Bound SARS Chymotrypsin-Like Cysteine Proteinase Predicted by Multiple Molecular Dynamics Simulations: Catalytic Efficiency Regulated by Substrate Binding

Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain

Estimation of solvation entropy and enthalpy via analysis of water oxygen-hydrogen correlations

Structure and dynamics of SARS coronavirus main proteinase (M pro)

Structural and evolutionary analysis indicate that the sars-COV-2 mpro is a challenging target for smallmolecule inhibitor design

From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design

On the Mode of Activation of the Catalytically Essential Sulfhydryl Group of Papain

Steady-state and pre-steadystate kinetic evaluation of severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro cysteine protease: Development of an ion-pair model for catalysis

Evidence for Substrate Binding-Induced Zwitterion Formation in the Catalytic Cys-His Dyad of the SARS-CoV Main Protease

On the Reactivity of the Thiol Group of Thiolsubtilisin

Mechanism for Controlling the Dimer-Monomer Switch and Coupling Dimerization to Catalysis of the Severe Acute Respiratory Syndrome Coronavirus 3C-Like Protease

The Protein Data Bank / Biopython

Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design

Structure of Mpro from COVID-19 virus and discovery of its inhibitors

Structure of alpha-Chymotrypsin Refined at 1.68 A Resolution

Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease

Time-averaged distributions of solute and solvent motions: Exploring proton wires of GFP and PfM2DH

Simmerling C. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

Mutation of glu-166 blocks the substrate-induced dimerization of SARS coronavirus main protease

Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode

Critical assessment of the important residues involved in the dimerization and catalysis of MERS Coronavirus Main Protease

SARS CoV main proteinase: The monomer-dimer equilibrium dissociation constant

Mutation of glu-166 blocks the substrate-induced dimerization of SARS coronavirus main protease

Without Its N-Finger, the Main Protease of Severe Acute Respiratory Syndrome Coronavirus Can Form a Novel Dimer through Its C-Terminal Domain

The moderately efficient enzyme: Evolutionary and physicochemical trends shaping enzyme parameters

Substrate specificity profiling of SARS-CoV-2 Mpro protease provides basis for anti-COVID-19 drug design

Protease (3CL pro ) IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS *

Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-like

Substrate and inhibitor-induced dimerization and cooperativity in caspase-1 but not caspase-3

The authors thank Dr. Andrei Golosov for his important contributions to the WATMD parts of this work, and helpful suggestions during the manuscript preparation.